MedPath

ctDNA-based Minimal Residual Disease Detection for Resected Pancreatic Adenocarcinoma

Conditions
Pancreatic Cancer Resectable
Registration Number
NCT05479708
Lead Sponsor
BAIYONG SHEN
Brief Summary

Short-term relapse and poor survival are prevalent in patients with pancreatic adenocarcinoma (PAAD) after surgeries. Despite the importance of adjuvant treatments for resected PAAD patients, there is currently no suitable biomarker to identify those individuals with high risk of recurrence and inform therapeutic decision making. In this study, we aim to examine whether postoperative circulating tumor DNA (ctDNA) could be used as a biomarker for early detection of minimal residual disease (MRD) and predicting relapse in resected PAAD through high-depth targeted next-generation sequencing.

Detailed Description

Not available

Recruitment & Eligibility

Status
ENROLLING_BY_INVITATION
Sex
All
Target Recruitment
150
Inclusion Criteria
  • Pathologically diagnosed pancreatic adenocarcinoma (stage I-III)
  • KRAS mutations identified in resected tumor tissues
  • Margin negative (R0) or no imaging recurrence/metastasis and CA 19-9<37 U/ml in postoperative 4-8 weeks (before adjuvant chemotherapy)
  • Receiving adjuvant chemotherapy
  • ECOG 0-2
  • Signed informed consent
Exclusion Criteria
  • With serious internal medicine diseases, infectious diseases, other solid tumors (except PAAD) or hematologic disorders
  • Distant organ metastasis or malignant ascites
  • Receiving neo-adjuvant therapy before surgery
  • Imaging recurrence/metastasis or CA 19-9>37 U/ml in postoperative 4-8 weeks (before adjuvant chemotherapy)
  • Pregnant or breastfeeding at time of enrollment
  • Prior transplantation of bone marrow, stem cell or organ

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Death and overall survival3 years

Overall survival difference between MRD-positive and MRD-negative patients

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

🇨🇳

Shanghai, Shanghai, China

Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
🇨🇳Shanghai, Shanghai, China

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.